Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organ Preservation Strategy Using ICB in CRC and GEC
NCT06410534Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Sep 2025
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in colorectal cancer (CRC) and gastroesophageal junction cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Clinical Complete Response or Near-Complete Response at 24 weeks. Planned start Sep 2025; status: withdrawn.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06410534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06410534.